-
1
المؤلفون: Sandrine Mansard, Philippe Saiag, Hervé Maillard, Amine Denden, Caroline Robert, Laurent Mortier, S. Dalac-Rat, Charlée Nardin, Olivier Dereure, Thierry Lesimple, Laurent Machet, Eve-Marie Neidhardt, Florent Grange, Alexandra Szenik, Caroline Dutriaux, Christophe Bedane, Céleste Lebbé, Jean-Jacques Grob
المساهمون: HAL UVSQ, Équipe, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], Service de dermatologie, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Lille, Université de Lille, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Léon Bérard [Lyon], Centre Eugène Marquis (CRLCC), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Francois Rabelais [Tours], Service de Dermatologie [CHU Limoges], CHU Limoges, Service de dermatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Novartis Pharma S.A.S., CHU Bordeaux [Bordeaux], Amgen, Bristol-Myers Squibb, BMS, Pfizer, Merck, Novartis, Roche, Sanofi, Meso Scale Diagnostics, MSD, Novartis Pharma, Les Laboratories Pierre Fabre, This work was supported by Novartis Pharma S.A.S. , France., Philippe Saiag has received personal fees from Amgen, Bristol-Myers Squibb, MSD, Merck-Serono, Pfizer, Roche-Genentech, Pierre Fabre, Sanofi and Novartis, he has received non-financial support from Bristol-Myers Squibb, MSD, Roche-Genentech and Novartis, and has received a funding grant from Roche-Genentech., Céléste Lebbe has received honoraria from BMS, MSD, Roche, Novartis, Amgen, Merck, Pierre Fabre, Pfizer and Incyte, has acted as a consultant or has served as a member of an advisory board for BMS, and has received travel grant support from BMS and MSD., Jean-Jacques Grob has received honoraria from BMS, MSD, Merck, Pfizer, Incyte, Novartis, Roche, Amgen and Pierre Fabre, has received travel grant support from BMS, MSD and Roche, and has acted as a consultant and advisor for BMS, MSD, Roche, Novartis, Amgen, Merck, Pierre Fabre, Pfizer and Incyte., Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)
المصدر: European Journal of Cancer
European Journal of Cancer, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
European Journal of Cancer, Elsevier, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Oncology, Cancer Research, medicine.medical_specialty, Pyridones, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Pyrimidinones, 030204 cardiovascular system & hematology, Regression tree, 03 medical and health sciences, BRAF V600-mutation, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Trametinib, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Prospective Studies, Stage (cooking), Prospective cohort study, education, neoplasms, Melanoma, Aged, Neoplasm Staging, education.field_of_study, Proportional hazards model, business.industry, Dabrafenib, Imidazoles, Middle Aged, medicine.disease, 3. Good health, 030220 oncology & carcinogenesis, Mutation, Disease Progression, Female, business, Brain metastasis, medicine.drug
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7270e6beefeb71081cde6deee2aa0af2Test
https://hal.science/hal-03401780Test -
2
المؤلفون: Matthew Squires, Victoria Atkinson, Eduard Gasal, James Larkin, Richard F. Kefford, James Garrett, Axel Hauschild, Daniel Gusenleitner, Vanna Chiarion-Sileni, Caroline Robert, John M. Kirkwood, Jan C. Brase, Catarina D. Campbell, Mario Mandalà, Dirk Schadendorf, Reinhard Dummer, Mario Santinami, Georgina V. Long, Keith T. Flaherty
المساهمون: University of Zurich, Dummer, Reinhard
مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Salvage therapy, 610 Medicine & health, Placebo, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Medicine, Survival rate, Trametinib, business.industry, 10177 Dermatology Clinic, Dabrafenib, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, Biomarker (medicine), 2730 Oncology, business, medicine.drug
وصف الملف: 841_Dummer_R._et_al._Adjuvant_dabrafenib_plus_trametinib_versus_placebo_in_patients_with_resected,_BRAFV600_mutant,_stage_III_melanoma_etc_Lancet_Oncology_2020.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8deeff612b475730ab4040608e0e18baTest
https://www.zora.uzh.ch/id/eprint/187679Test/ -
3
المؤلفون: Dirk Schadendorf, Caroline Dutriaux, Caroline Robert, Reinhard Dummer, John M. Kirkwood, Marta Nyakas, Mario Mandalà, Laurent Mortier, Axel Hauschild, Kohinoor Dasgupta, Monique Tan, Eduard Gasal, James Larkin, Jacob Schachter, Vanna Chiarion Sileni, Andrew Haydon, Victoria Atkinson, Mario Santinami, Georgina V. Long
مصطلحات موضوعية: Oncology, Trametinib, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Melanoma, Mutant, Medizin, Dabrafenib, Placebo, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, Stage (cooking), business, Adjuvant, 030215 immunology, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f486f97df79593e3e9abb490624153c0Test
-
4
المؤلفون: Aisha Masood, Keith T. Flaherty, Reinhard Dummer, Erika Richtig, Hussein Abdul-Hassan Tawbi, Céleste Lebbé, Neha Pakhle, Caroline Robert, Paul Nathan, Naoya Yamazaki, Mario Mandalà, Dirk Schadendorf, Victoria Atkinson, Paolo A. Ascierto, Ana Arance, Antoni Ribas, Georgina V. Long, Eduard Gasal
مصطلحات موضوعية: Trametinib, Cancer Research, business.industry, Melanoma, medicine.medical_treatment, Anti pd 1, Mutant, Medizin, Dabrafenib, medicine.disease, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Cancer research, Medicine, In patient, business, 030215 immunology, medicine.drug, Advanced melanoma
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c75c8d57ccfac94d27b8372d465da2a0Test
-
5
المؤلفون: Caroline Robert, Jacob Schachter, Thierry Lesimple, C. Dutriaux, Dirk Schadendorf, Monique Tan, Axel Hauschild, Georgina V. Long, R. Dummer, Eduard Gasal, Mario Santinami, Kohinoor Dasgupta, James Larkin, Mario Mandalà, Andrew M. Haydon, John M. Kirkwood, Vanna Chiarion Sileni, Laurent Mortier, Victoria Atkinson, Marta Nyakas, Ruth Plummer
المساهمون: University of Zurich
مصطلحات موضوعية: Male, Oncology, Skin Neoplasms, medicine.medical_treatment, Medizin, Administration, Oral, 2700 General Medicine, 030204 cardiovascular system & hematology, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Oximes, Medicine, 030212 general & internal medicine, Neoplasm Metastasis, Melanoma, Trametinib, Imidazoles, Follow up studies, 10177 Dermatology Clinic, General Medicine, Middle Aged, Female, Adjuvant, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, 610 Medicine & health, Pyrimidinones, Disease-Free Survival, 03 medical and health sciences, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Humans, Stage III melanoma, Protein Kinase Inhibitors, Survival analysis, Aged, Neoplasm Staging, business.industry, Dabrafenib, Survival Analysis, Clinical trial, Mutation, business, Follow-Up Studies
وصف الملف: 848_Dummer_R._et_al._Five-Year_Analysis_of_Adjuvant_Dabrafenib_plus_Trametinib_in_Stage_III_Melanoma_NEJM_2020.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d710d2b0f671e5dafc838391b9965d4aTest
https://www.zora.uzh.ch/id/eprint/190018Test -
6
المؤلفون: Hussein Abdul-Hassan Tawbi, Victoria Atkinson, Paul Nathan, Naoya Yamazaki, Radha Ramesh, Daniel Gusenleitner, Paolo A. Ascierto, Céleste Lebbé, Eduard Gasal, Dirk Schadendorf, Reinhard Dummer, Caroline Robert, Jan C. Brase, Keith T. Flaherty, Georgina V. Long, Mario Mandalà, Antoni Ribas, Kelly Biette, Erika Richtig, Ana Arance
مصطلحات موضوعية: Trametinib, Oncology, Cancer Research, medicine.medical_specialty, business.industry, First line, Melanoma, Mutant, Medizin, Dabrafenib, medicine.disease, Peripheral blood, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, business, Complete response, 030215 immunology, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4427df5cbb6f0c621237dae3895445f3Test
-
7
المؤلفون: Eduard Gasal, Paul Nathan, Antoni Ribas, Neha Pakhle, Victoria Atkinson, Céleste Lebbé, Dirk Schadendorf, Mario Mandalà, Daniel Gusenleitner, Paolo A. Ascierto, Aisha Masood, Erika Richtig, Catarina D. Campbell, Reinhard Dummer, Ana Arance, Keith T. Flaherty, Hussein Abdul-Hassan Tawbi, Naoya Yamazaki, Georgina V. Long, Caroline Robert, Jan C. Brase
المساهمون: University of Zurich, Dummer, Reinhard
مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Skin Neoplasms, Medizin, Cohort Studies, 0302 clinical medicine, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, Neoplasm Metastasis, Immune Checkpoint Inhibitors, Melanoma, Trametinib, MEK inhibitor, Imidazoles, 10177 Dermatology Clinic, General Medicine, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, Biomarker (medicine), Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, Mutation, Missense, 610 Medicine & health, Genetics and Molecular Biology, Pyrimidinones, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Young Adult, 1300 General Biochemistry, Genetics and Molecular Biology, Internal medicine, medicine, Biomarkers, Tumor, Humans, Protein Kinase Inhibitors, Aged, business.industry, Dabrafenib, medicine.disease, Clinical trial, Regimen, 030104 developmental biology, General Biochemistry, business
وصف الملف: 870_Dummer_R._et_al._Combined_PD-1,_BRAF_and_MEK_inhibition_in_advanced_BRAF-mutant_melanoma_Nature_Medicine_2020.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b17ee96d80a3281cdd7448c58c9110fTest
https://www.ncbi.nlm.nih.gov/pubmed/33020648Test -
8
المؤلفون: Jean-Jacques Grob, Keith T. Flaherty, Claus Garbe, Antoni Ribas, Dirk Schadendorf, Igor Bondarenko, E. Levchenko, Axel Hauschild, Daniil Stroyakovskiy, Boguslawa Karaszewska, Eduard Gasal, Jacob Schachter, Paul Burgess, Vanna Chiarion Sileni, Monique Tan, Michael A. Davies, Paul Nathan, Georgina V. Long, Caroline Robert
مصطلحات موضوعية: Trametinib, Oncology, Cancer Research, medicine.medical_specialty, Metastatic melanoma, business.industry, Mutant, Medizin, Dabrafenib, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Overall survival, Medicine, In patient, business, 030215 immunology, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b84accdf645a3febf71438325b82001Test
-
9
المؤلفون: Georgina V. Long, Paul Nathan, Mahrukh M. Syeda, David Polsky, Michael A. Davies, Eduard Gasal, Dirk Schadendorf, Jean-Jacques Grob, Mahtab Marker, Keith T. Flaherty, Caroline Robert, Antoni Ribas, Jan C. Brase, Matthew Squires, Jennifer M. Wiggins, Broderick Corless
مصطلحات موضوعية: Trametinib, Cancer Research, Prognostic factor, Metastatic melanoma, business.industry, Medizin, Dabrafenib, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Oncology, chemistry, Circulating tumor DNA, 030220 oncology & carcinogenesis, Lactate dehydrogenase, medicine, Cancer research, In patient, business, 030215 immunology, medicine.drug, Advanced melanoma
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b86e39c367b57f167b9e41cff430785Test
-
10
المؤلفون: Jacob Schachter, Dirk Schadendorf, Eduard Gasal, Laurent Mortier, Marta Nyakas, Egbert de Jong, Caroline Dutriaux, Reinhard Dummer, Mario Santinami, Georgina V. Long, John M. Kirkwood, Mario Mandalà, Victoria Atkinson, Vanna Chiarion-Sileni, Andrew Haydon, Caroline Robert, Christine-Elke Ortmann, James Larkin, Richard F. Kefford, Axel Hauschild
مصطلحات موضوعية: Trametinib, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Mutant, Hazard ratio, Medizin, Dabrafenib, Placebo, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, Stage III melanoma, business, Adjuvant, 030215 immunology, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f42511b4b46cd8c4fde9d100d74a0872Test